异丙酚联合依达拉奉对大脑缺血再灌注损伤后gfap表达的影响异丙酚联合依达拉奉对大鼠脑缺血再灌注损伤后gfap表达的影响.doc

异丙酚联合依达拉奉对大鼠脑缺血-再灌注损伤后GFAP表达的影响 亓海燕，王端玉，金延武 ( [摘要] 目的 观察异丙酚联合依达拉奉对大鼠脑局灶性缺血-再灌注损伤后胶质纤维酸性蛋白(GFAP)表达的影响。方法 健康雄性Wistar大鼠72只随机分为脑缺血再灌注组(I/R)、依达拉奉干预组(ED)和异丙酚联合依达拉奉组(PE)，采用线栓法制作大鼠脑缺血再灌注模型；缺血2 h后，设再灌注4 h、12 h、24 h、48 h组，测定大鼠神经功能缺损评分后，取脑，采用TTC染色检测大鼠脑梗死体积，采用SABC三步法免疫组织化学法测定大鼠脑梗死边缘带GFAP表达。结果I/R组再灌注后4 h已出现梗死灶，随着时间的延长，梗死体积逐渐增大，24 h梗死体积最大；ED、PE组梗死边缘带GFAP表达量较IR组表达量增加且表达高峰提前(P0.05)。ED、PE组与I/R组时间点对点相比，梗死灶体积明显缩小(P0.05)，神经功能缺损评分明显减少(P0.05)。结论 依达拉奉能降低大鼠脑缺血再灌注后GFAP表达水平，减少脑梗死的面积，减轻脑缺血再灌注后神经功能损伤程度，联合应用异丙酚对其缺血再灌注损伤的保护作用无显著影响。 [关键词] 依达拉奉；异丙酚；脑缺血再灌注；大鼠；胶质纤维酸性蛋白 [中图分类号] 　R743.3　*, WANG Duan-yu. JIN Yan-wu. *Medical School of Guiyang, Guiyang, 550004, Guizhou, China [Abstract] Objective To investigate the effect of propofol with edaravone on the expression of GFAP after focal brain ischemia-reperfusion injury in rats. Methods The middle cerebral artery (MCA) focal cerebral ischemia-reperfusion rat models were used by thread occlusion method. Rats were randomly divided into focal cerebral ischemia group(I/R), Edaravone-treating group(ED) and Edaravone with Propofol-treating group(PE), whose arteries were occlusive for 2 hours. All groups were further divided into 4 sectors according to the reperfusion time (4 h, 12 h, 24 h, and 48 h). After determined the score of neurological deficits, the infarct volume of brain ischemic damage was estimated by TTC staining. SABC method was used to test the expression of brain tissue GFAP. Results The infarction volume was detected at 4 h after focal brain ischemia-reperfusion. As time prolonging, the infarction volume became more and more large. GFAP expression of brain tissue increased in group I/R and ED. Compared with control group, the infarction volumes were significantly deflated (P0.05); the score of neurological deficits were also decreased (P0.05). Conclusion Edaravone can decrease the expression of GFAP and cerebral infarction volume and attenuate neurologic function deficits after cerebral ischemia-reperfusion in rats. [Key words] Edaravone